Stockreport

EXCLUSIVE: Soligenix Starts Confirmatory Late-Stage Trial For HyBryte For Type Of Blood Cancer [Yahoo! Finance]

Soligenix, Inc.  (SNGX) 
NASDAQ:AMEX Investor Relations: soligenix.com/investors
PDF On Monday, Soligenix, Inc. (NASDAQ: SNGX ) said it has opened patient enrollment for its confirmatory Phase 3 study evaluating HyBryte (synthetic hypericin) for cutaneo [Read more]